Brief: MannKind Corp reports Initial Meal Challenge Results Comparing Afrezza Head-To-Head With Multiple Daily Injections And Insulin Pumps
11/03/2024 10:17
March 11 (Reuters) - MannKind Corp MNKD.O :
* INHALE-3 STUDY’S INITIAL MEAL CHALLENGE RESULTS COMPARING
AFREZZA® HEAD-TO-HEAD WITH MULTIPLE DAILY INJECTIONS (MDI) AND
INSULIN PUMPS
* MANNKIND: POST-MEAL HYPERGLYCEMIA REDUCED BY 20% WITH
INHALED
INSULIN VERSUS RAPID-ACTING INSULIN DELIVERED THROUGH MDI OR
INSULIN PUMPS
* MANNKIND - SUBJECTS UTILIZING INHALED INSULIN EXPERIENCED
A 22%
DECREASE IN MEAN GLUCOSE EXCURSIONS IN FIRST TWO HOURS COMPARED
TO STANDARD OF CARE
Source text for Eikon: ID:nGNX6s2f76
Further company coverage: MNKD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MannKind
See all newsBrief: MannKind Enters Data-Rich Development Period With Completion Of Randomization In Phase 1B Inflo-1 Study And Enrollment Of First Patient In Phase 2 Inflo-2 Trial For Nintedanib Dpi In Patients With Ipf
U.S. STOCKS ON THE MOVE-Dell, Gap, Costco
MannKind rises after FDA approves inhaled insulin for children
US FDA approves MannKind's inhaled insulin for children (updated)
US FDA approves MannKind's inhaled insulin for children